AMSBIO: Circulating Tumor DNA Reference Standards

AMSBIO announce the launch of a new range of circulating tumor DNA (ctDNA) Reference Standards for cancer disease management research.

A critical goal in cancer disease management is early detection. When detected early, cancer progression can be arrested using techniques such as targeted therapy, chemotherapy and surgery thereby increasing the chances of survival and a higher quality of life. Liquid biopsy offers the promise of providing a quick, non-invasive and cost-effective alternative to surgical biopsies, allowing tumor analysis through a simple blood sample. Traces of the ctDNA in the blood offer the potential of not only earlier cancer detection, but may also guide therapy selection, enabling routine monitoring of cancer to assess minimal residual disease, and resistance monitoring during treatment.

Advances in Next-Generation Sequencing (NGS) and digital PCR (dPCR) are accelerating the development of quantitative assays that can the detect low amounts of mutant DNA present in blood samples, often down to 1 in 1000 mutant alleles (0.1%) or lower. These developments have enabled non-invasive cancer profiling of associated somatic variants from ctDNA.

AMSBIO now offers ctDNA Reference Standards highly characterized, quantitative multiplex quality controls to support the development of assays. These standards are engineered to mimic the fragmentation profile of nucleosomal ctDNA (~166 bp) observed in patient samples across are range of allele frequencies. Pre-validated by digital PCR, cancer-associated mutations are included across EGFR, PIK3CA, NRAS and KRAS samples.

Based on CRISPR/Cas9 isogenic cell lines, AMSBIO Patient-Like circulating ctDNA is available as purified DNA or in a synthetic plasma. These reference standards can be directly incorporated into assay optimization, as an essential control for evaluating of limits of detection and specificity.

For further information on ctDNA reference standards please visit http://www.amsbio.com/ct-DNA-reference-standard.aspx or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / info@amsbio.com. 

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO can draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective. Custom services include stable cell line production, CRISPR/Cas9 Genome Editing, lentivirus and adenovirus production, large scale protein production and a comprehensive portfolio of antibody services.

Worldwide HQ 

AMS Biotechnology (AMSBIO)

184 Milton Park
Abingdon

Oxon OX14 4SE

UK
Tel: +44-1235-828200
Fax: +44-1235-820482
Email: info@amsbio.com 
Web www.amsbio.com

 

North American HQ

 

AMSBIO LLC
1035 Cambridge Street
Cambridge
MA 02141
USA
Tel: +1.617.945.5033 
Tel:+ 1.800.987.0985 (toll free)
Email: info@amsbio.com  
Web www.amsbio.com